Janux Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.12.24	Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Businesswire)
03.12.24	Janux Therapeutics Announces Proposed Public Offering (Businesswire)
25.11.24	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies (Businesswire)
06.11.24	Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (Businesswire)
07.08.24	Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (Businesswire)
22.07.24	Janux Therapeutics Announces Updates to Board of Directors (Businesswire)
07.05.24	Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (Businesswire)
08.03.24	Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Businesswire)
29.02.24	Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Businesswire)
27.02.24	Janux Therapeutics Announces Proposed Public Offering of Common Stock (Businesswire)
26.02.24	Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors (Businesswire)
20.02.24	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 (Businesswire)
08.01.24	Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer (Businesswire)
07.11.23	Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (Businesswire)
08.08.23	Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (Businesswire)
17.07.23	Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Businesswire)
17.07.23	Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs (Businesswire)
09.05.23	Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (Businesswire)
24.04.23	Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences (Businesswire)
20.04.23	Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors (Businesswire)
10.03.23	Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Businesswire)
27.12.22	Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors (Businesswire)
22.11.22	Janux Therapeutics to Present at Upcoming Investor Conferences in November (Businesswire)
10.11.22	Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (Businesswire)
12.10.22	Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Roche Hldg G	273.90	5.39 %	K V
Novartis	102.56	2.44 %	K V
Nestle	74.08	1.38 %	K V
Kuehne+Nagel Int	149.45	0.88 %	K V
Lonza Grp	531.60	0.83 %	K V
Swiss Re	146.50	-0.37 %	K V
ABB	57.02	-0.52 %	K V
CieFinRichemont	150.80	-0.53 %	K V
Logitech Intl	86.16	-0.71 %	K V

Janux Therapeutics Aktie VALOR 111742522 / ISIN US47103J1051

Nachrichten zu Janux Therapeutics Inc Registered Shs

Aktien Top/Flop

Janux Therapeutics Peer Group Nachrichten

Meistgelesene Nachrichten